The BOLERO-2 registration trial showed that the combination of everolimus and exemestane resulted in higher response rates and longer median progression-free survival (mPFS) than the placebo-exemestane treatment, but the approximately 6 months difference in overall survival (OS) did not reach statistical significance ( 2 , 3 ).
← all excerpts
The role of everolimus in metastatic breast cancer and possibilities of moving forward-a narrative review.
1
—
—